Zhao Min, Li Hongbing, Li Lei, Zhang Yijie
Department of Respiratory Medicine, Henan University Huaihe Hospital, Kaifeng, Henan 475000, P.R. China.
Exp Ther Med. 2014 May;7(5):1403-1407. doi: 10.3892/etm.2014.1574. Epub 2014 Feb 21.
The aim of the present study was to investigate the effects of a gemcitabine plus platinum (GP) regimen combined with dendritic cell-cytokine induced killer (DC-CIK) immunotherapy on the recurrence and survival rate in patients with non-small cell lung cancer (NSCLC). Patients (n=157) with stage III NSCLC that had received surgery were randomly divided into a control group and an observation group. The control group was administered with a GP regimen and the observation group received GP chemotherapy that was based on DC-CIK cell immunotherapy in addition to SC-CIK cell immunotherapy here. The two groups were followed up for 36 months and their postoperative cellular immune function, disease-free survival time, cumulative recurrence rate and cumulative survival rate was analyzed. The percentages of CD3CD4 T lymphocytes, natural killer cells and the CD4/CD8 ratio were identified to be significantly increased following treatment compared with those observed prior to treatment in the control and observation groups; conversely, the CD3CD8 T lymphocyte percentage decreased significantly (P<0.05). Furthermore, the results of the patients in the observation group were significantly better compared with the control group based on these indicators (P<0.05). The median disease-free survival time of patients in the observation group (28 months) was identified to be significantly longer than that of the control group (22 months; P<0.05), the three-year cumulative recurrence rate in the observation group (47.37%) was significantly lower than that of the control group (76.92%; P<0.05) and the three-year cumulative survival rate of the patients in the observation group (58.23%) was significantly higher than that of the control group patients (37.14%; P<0.05). In conclusion, the GP regimen combined with DC-CIK immunotherapy significantly improved the immune cell function in the postoperative NSCLC patients, in addition to reducing postoperative tumor recurrence and prolonging the survival time of patients with NSCLC.
本研究旨在探讨吉西他滨联合铂类（GP）方案联合树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）免疫疗法对非小细胞肺癌（NSCLC）患者复发率和生存率的影响。157例接受手术的Ⅲ期NSCLC患者被随机分为对照组和观察组。对照组采用GP方案治疗，观察组在此基础上接受基于DC-CIK细胞免疫疗法的GP化疗以及SC-CIK细胞免疫疗法。两组随访36个月，分析其术后细胞免疫功能、无病生存时间、累积复发率和累积生存率。结果显示，与治疗前相比，对照组和观察组治疗后CD3CD4 T淋巴细胞、自然杀伤细胞百分比及CD4/CD8比值均显著升高；相反，CD3CD8 T淋巴细胞百分比显著降低（P<0.05）。此外，基于这些指标，观察组患者的结果明显优于对照组（P<0.05）。观察组患者的中位无病生存时间（28个月）显著长于对照组（22个月；P<0.05），观察组三年累积复发率（47.37%）显著低于对照组（76.92%；P<0.05），观察组患者的三年累积生存率（58.23%）显著高于对照组患者（37.14%；P<0.05）。总之，GP方案联合DC-CIK免疫疗法除了可降低NSCLC患者术后肿瘤复发率和延长生存期外，还能显著改善术后NSCLC患者的免疫细胞功能。
